|
Issuer: SHS Gesellschaft für Beteiligungsmanagement mbH
/ Key word(s): Investment/Private Equity
SHS Capital acquires a majority stake in the therapy and rehabilitation home care provider MTR. The aim of the investment is to further grow the core business and support the nationwide expansion that has already been initiated. Medizintechnik Rostock GmbH is a home care provider for therapy devices, founded in 1994 and currently employs around 200 people. As a quality leader in Germany, MTR is a partner of over 80 health insurance companies and carried out over 140,000 therapy fittings in the areas of movement, electro and compression therapy in 2023. Of the three areas of application for MTR devices, the largest is movement therapy. The continuous passive motion (CPM) devices are used to help patients restore joint mobility after operations such as knee and hip procedures or shoulder and elbow surgeries. Another area is electrotherapy, which uses electrical impulses to stimulate muscles, relieve pain or treat neurological disorders. The newest area is compression therapy. The focus here is on the treatment of lymphoedema and venous disorders. Using devices for intermittent pneumatic compression (IPC), sequential pressure is applied to the affected areas to enhance circulation and reduce swelling. If a physician prescribes therapy with an MTR device for a patient as part of the recovery process, the costs are covered by the health insurance in the vast majority of cases. The therapy devices are provided by MTR to patients during the required rehabilitation phase under a rental model. The company supports the patients in their homes with its in-house service and training staff to start their therapy. The staff provides on-site instructions for correct device use and calibrates the device precisely to the individual requirements of each patient. This service is carried out by MTR's own staff and thus guarantees not only consistently high quality and patient care, but also fast and individualised deliveries to the patients. Thanks to this high quality of service, MTR enjoys an excellent reputation among prescribing physicians and has been able to continuously grow its patient base in recent years. "Together with SHS, MTR will realise an important step on its expansion and growth path. We are excited to leverage SHS’ healthcare sector expertise and network and look forward to working closely together to successfully assist even more patients across Germany in their health recovery journeys," explains MTR shareholder Andreas Markschies. "I am very pleased that we have found the right partner for our company, who understands and respects our company history and will support us in achieving our further goals," says MTR shareholder Matthias Liewehr. "We are delighted to have the opportunity to support the continued growth of MTR. Since its foundation 30 years ago, the focus has always been on optimising patient care, which has established MTR as a quality leader in its field. We want to continue this success story together with the management and thus give even more patients access to these therapies. We will benefit from our expertise and experience in the home care sector, which we have already demonstrated in former investments, such as Medigroba GmbH," says SHS Capital Senior Investment Manager Tobias Fuchs.
About Medizintechnik Rostock GmbH: Medizintechnik Rostock GmbH, founded in 1994, is a home care provider specialising in the provision of medical devices, medical technology and medical aids in specific fields of movement, electro, and compression therapy. The company employs approximately 200 people at the main locations in Rostock and Berlin, as well as in the nationwide field service. The main focus is on providing medical aids in the home environment. Since many years, the company has been a contractual partner of almost all statutory health insurance companies in Germany, as well as professional associations and other service providers. About SHS Gesellschaft für Beteiligungsmanagement mbH SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. "Building European Healthcare Champions" is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of around € 270 million. Press contact:
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
